Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s disease
Jillian H. Kluss, Patrick A. Lewis, Elisa Greggio
Abstract
AREAS COVERED: In this review, we will provide an update on the current status of drugs and other technologies that have emerged in recent years and provide an overview of their efficacy in ameliorating LRRK2 kinase activity and overall safety in animal models and humans. EXPERT OPINION: The growth of both target discovery and innovative drug design has sparked a lot of excitement for the future of how we treat Parkinson's disease. Given the immense focus on LRRK2 as a therapeutic target, it is expected within the next decade to determine its therapeutic properties, or lack thereof, for PD.
Topics & Concepts
LRRK2DiseaseParkinson's diseaseDrug discoveryMedicineLeucine-rich repeatKinaseDrug targetDrug developmentDrugBioinformaticsPharmacologyNeuroscienceBiologyInternal medicineGeneticsParkinson's Disease Mechanisms and TreatmentsPlant biochemistry and biosynthesisPlant Gene Expression Analysis